Biguanides and sulfonylureas are by far the most heavily prescribed type 2 diabetes (T2D) drug classes. However, several branded agents are jostling for position as second-line treatment options, including the DPP-IV inhibitors Januvia and Tradjenta, the SGLT-2  inhibitors Jardiance, Invokana, and Farxiga, the GLP-1 receptor agonists Victoza and Trulicity, and the insulins. Optimized drug treatment can improve glycemic control, which can decrease the risk of specific comorbid conditions in T2D, including vascular and hepatic sequelae. In an increasingly competitive and congested market, brand differentiation and understanding of patient characteristics are ever more critical for marketers.

Questions Answered

  • What is the patient share in type 2 diabetes for metformin, sulfonylureas, Novo Nordisk’s Victoza, and Sanofi’s Lantus?
  • What are the demographic characteristics and clinical profiles of type 2 diabetes patients on SGLT-2 inhibitors or DPP-IV inhibitors?
  • What are the key risk factors, comorbidities, and coprescribed therapies by patient segment for type 2 diabetes?
  • How do patient cohorts for type 2 diabetes compare in care utilization and outcomes (physician visits and other healthcare encounters)?
  • What insurance type and provider do type 2 diabetes patients have?
  • What are the reimbursed and out-of-pocket costs?

Product Description

Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced using DRG’s comprehensive real-world data repository.

Markets Covered

United States


Type 2 Diabetes Patient Profiler sources demographic, clinical, and cost-based metrics using DRG’s real-world data repository.

Key Companies

Boehringer Ingelheim, Janssen, Eli Lilly, Merck & Co., Novo Nordisk, and Sanofi.

Key Drugs

Biguanides, Humalog, Invokana, Januvia, Jardiance, Lantus, Levemir, NovoLog, premixed insulin, sulfonylureas, Tradjenta, Toujeo, Trulicity, and Victoza.

Table of contents

  • Type 2 Diabetes - Current Treatment - Detailed, Expanded Analysis: Patient Profiler (US)
    • Patient Profiler - Type 2 Diabetes - 2018 - US

Author(s): Kerri Brown, M Pharm

Kerri Brown, M.Pharm., is an analyst with Decision Resources Group, focused on finding stories in data and developing products to inform strategic decisions in the hemophilia and diabetes spaces. Kerri holds a master of pharmacy degree from King’s College London with 1st class honors. Prior to joining DRG, she was a national clinical educator at a UK diabetes start-up, and has extensive experience of diabetes medical devices. Kerri has worked at AstraZeneca, and as a pharmacist in a national psychiatric clinical trial center. In addition to her work at DRG, Kerri is a practicing pharmacist with extensive clinical experience of UK physician prescribing in diabetes.

Related Reports

Type 2 Diabetes - Landscape & Forecast - Disease Landscape & Forecast

View Details

Type 2 Diabetes | Disease Landscape and Forecast | G7 | 2020

The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in th...

View Details

Type 2 Diabetes - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 2 diabetes patient...

View Details

Type 2 Diabetes - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) Dashboard

Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of...

View Details